Search results
New treatment for advanced prostate cancer put on FDA fast track
WXYZ-TV Detroit· 15 hours agoBiontech has announced that their new antibody-drug conjugate candidate aimed at treating advanced ...
15 Life-Altering Moments In The Lives Of Cancer Survivors That Will Give You A New Perspective On...
BuzzFeed via Yahoo News· 6 days agoAnton Dobrea / Getty Images 9."I am 78 years old and at the age of 70, I was diagnosed with prostate...
This Weird Habit Is One of the Most Common Signs of Brain Cancer, According to Neurologists
Parade via AOL· 6 days agoMina...tumors." But how? Even some of your habits may be a signal you have brain cancer. Dr. Lobbous...
AstraZeneca's Combination Cancer Drug For Advanced Breast Cancer Study Flunks Late-Stage Trial -...
Benzinga· 7 days agoThe study did not meet the dual primary endpoints of improvement in overall survival (OS) versus...
Lantheus (LNTH) Gains 33.3% YTD: What's Driving the Stock?
Zacks via Yahoo Finance· 7 days agoImage Source: Zacks...A Look at Estimates LNTH’s EPS for fiscal 2024 and 2025 is projected to grow...
AstraZeneca's (AZN) Truqap Misses Endpoints in TNBC Study
Zacks via Yahoo Finance· 7 days agoAstraZeneca's (AZN) phase III CAPItello-290 study evaluating Truqap plus chemotherapy in patients...
With iOnctura and Yellowstone, Syncona adds two cancer biotechs to growing portfolio
FierceBiotech· 5 days agoSyncona has added two up-and-coming cancer companies to its portfolio, ensuring the biotechs are armed with a combined total of over $100 million in series A and B funds.
Ryne Sandberg reflects on 'love, life, family and friends' as Cubs unveil his statue outside Wrigley...
Chicago Sun-Times· 2 days agoCubs great Ryne Sandberg set a series of goals when he was diagnosed with metastatic prostate cancer this past winter. “This was a guarantee for me,” Sandberg ...
Jazz drug for tremor fails study; Radiopharma drug developer ITM swaps CEOs
BioPharma Dive via Yahoo Finance· 4 days agoA medicine Jazz acquired in 2019 missed the goal of a Phase 2 study. Elsewhere, Vanda rejected two...
FDA Expands Orphan Drug Designation for SurVaxM, I | Newswise
Newswise· 4 days agoBUFFALO, N.Y. — The U.S. Food and Drug Administration (FDA) has expanded orphan drug designation for SurVaxM, a brain cancer immunotherapy born in the labs of Roswell Park ...